Voyager Acquisition rises as shareholders back VERAXA Biotech merger
13/03/2026 10:23
** Shares of healthcare-focused blank‑check firm Voyager Acquisition VACH.O rise 8.8% to $11.97 premarket ** Co says shareholders have approved its merger with Swiss biotech firm VERAXA Biotech AG ** VERAXA develops antibody-based medicines, which use lab-made immune proteins to target disease ** VACH says nearly all shareholders, or 99.67%, redeemed shares for cash ahead of the deal ** Trust account will hold about $885,556 after redemptions, co says ** Combined company expected to trade on Nasdaq under ticker VRXA, pending exchange approval ** Shares rose ~6% in 2025 (Reporting by Sahil Pandey in Bengaluru) ((Sahil.Pandey@thomsonreuters.com))